M&A Deal Summary |
|
|---|---|
| Date | 2021-06-14 |
| Target | Novellus Therapeutics |
| Sector | Life Science |
| Buyer(s) | Ernexa Therapeutics |
| Sellers(s) | Factor Bioscience |
| Deal Type | Divestiture |
| Deal Value | 125M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2018 |
| Sector | Life Science |
Ernexa Therapeutics is focused on providing cytokine-based therapy to treat patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. Ernexa Therapeutics was founded in 2018 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2021 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-08-13 |
Buzztime
Carlsbad, California, United States Buzztime delivers interactive entertainment and innovative technology that helps its customers acquire, engage, and retain their patrons. The company's tablets, mobile app, and technology offer engaging solutions to establishments that have guests who experience dwell time, such as in bars, restaurants, casinos, and senior living centers. Buzztime was founded in 1983 and is based in Carlsbad, California. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience developed the fastest, highest-efficiency method for reprogramming somatic cells to a pluripotent stem-cell state, a key invention now recognized by several patents. This technology, which enables the production of patient-specific cells for transplantation, has wide-ranging applications in personalized regenerative medicine. Factor Bioscience was founded in 2011 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Divestiture M&A Deals | 1 of 2 |
| State: Massachusetts M&A | 1 of 2 |
| Country: United States M&A | 1 of 2 |
| Year: 2021 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-11-19 |
Factor Bioscience - Dual-CAR T Programs
Cambridge, Massachusetts, United States Factor Bioscience's Dual-CAR T Programs are specifically designed to target patients with extramedullary disease (EMD), which we are referring to as TPST-2003 and are based in Cambridge, Massachusetts. |
Sell | - |
